Simulect® (basiliximab): warning against off-label use in cardiac transplantation Dear Healthcare Professional, 8th September[removed]Novartis, in association with the European Medicines Agency and the Medicines and Healt

First Page		Document Content
Date: 2014-10-14 07:41:11 Mycophenolic acid Ciclosporin Azathioprine Kidney transplantation Immunosuppression Medicine Immunosuppressants Yellow Card Scheme		Simulect® (basiliximab): warning against off-label use in cardiac transplantation Dear Healthcare Professional, 8th September[removed]Novartis, in association with the European Medicines Agency and the Medicines and Healt Add to Reading List Source URL: www.mhra.gov.uk Download Document from Source Website File Size: 268,90 KB Share Document on Facebook

	Advanced NLP in Healthcare DocID: 1aZw8 - View Document
	Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: an approach to improve the therapeutic index of highly toxic chemotherapy drugs DocID: 15PYF - View Document
	News Release Santen Announces Approval of Ikervis for EU Marketing Authorization March 25, 2015 , Osaka, Japan – Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Appli DocID: 15HaJ - View Document
	Facilitating protein SAR tables for peptide therapeutics - A practical approach to protein-naming for researchers and computers Jan Holst Jensen CEO and Founder, Biochemfusion DocID: 10o81 - View Document
	DJ-1 protects against cell death following acute cardiac ischemia–reperfusion injury DocID: ZTyp - View Document